On Monday, H.C. Wainwright adjusted its price target on shares of Compass Pathways (NASDAQ:CMPS), a company specializing in mental health care therapies, reducing it to $60 from the previous $120. The firm maintained its Buy rating on the stock despite the significant adjustment. The revision follows Compass Pathways' third-quarter financial report and corporate update on October 31, which included details on its primary product, COMP360.
Compass Pathways' COMP360, an oral psilocybin therapy currently in Phase 3 development for treatment-resistant depression (TRD), is at the core of the company's clinical efforts. The company's stock experienced a 23% drop, a stark contrast to the 1.4% decline in the XBI, an exchange-traded fund tracking the biotechnology index. The decline was mainly attributed to the announcement of delayed timelines for its pivotal trials, with top-line data for trial 1 (COMP 005) now expected in the second quarter of 2025, and trial 2 (COMP006) in the second half of 2026.
In response to these developments, Compass Pathways also revealed a restructuring plan aimed at reducing its workforce by 30% and discontinuing preclinical efforts that do not involve COMP360. The company's strategy is to focus on enrolling suitable patients for its ongoing trials and to prepare for a potential advisory committee meeting with the FDA before the product's approval.
Despite the setbacks and the subsequent reduction in the price target, H.C. Wainwright expressed continued confidence in the management's decision-making and the potential of COMP360 for treating depression. The new price target is still seen as offering considerable upside from the stock's current levels. The firm's reiteration of the Buy rating signals its anticipation of positive updates on the COMP360 program in the future.
In other recent news, Compass Pathways has reported its third-quarter earnings for 2024, revealing notable developments in its financial and operational activities. The mental health care company has experienced delays in its phase III clinical trials due to recruitment challenges, pushing the anticipated release of its COMP360 trial data to Q2 2025 for COMP005 and the second half of 2026 for COMP006. Despite these setbacks, RBC Capital Markets maintains a positive outlook on the company's prospects, with a new price target of $18, down from $23.
Compass Pathways has also announced a workforce reduction of approximately 30% and a pause to non-COMP360 preclinical efforts, as part of a strategic focus on the development of COMP360, a potential treatment for treatment-resistant depression (TRD). RBC Capital highlights that Compass Pathways could potentially exceed $1 billion in the TRD market with COMP360 therapy.
Even with a $13.6 million R&D tax credit, the company's cash burn for Q3 was $35.8 million. Nevertheless, Compass Pathways remains committed to the successful launch and commercial viability of COMP360, with data from over 1,000 patients expected from ongoing trials. The company is also preparing for the launch of COMP360 by ensuring delivery centers are ready and compliant with billing codes and regulations.
InvestingPro Insights
Recent InvestingPro data provides additional context to Compass Pathways' current financial situation and market performance. The company's market capitalization stands at $324.84 million, reflecting its position as a smaller player in the biotech sector. This valuation aligns with the challenges outlined in the article, particularly the delayed timelines for COMP360 trials and the subsequent restructuring plan.
InvestingPro Tips highlight some key aspects of CMPS's financial health. The company "holds more cash than debt on its balance sheet," which could be crucial as it navigates through the extended development timeline for COMP360. However, it's also noted that CMPS is "quickly burning through cash," a concern that may have contributed to the recent workforce reduction and focus on core projects.
The stock's recent performance has been challenging, with InvestingPro data showing a 25.31% decline in the past week and a 23.51% drop over the last month. This aligns with the 23% stock drop mentioned in the article following the company's Q3 report and timeline adjustments.
For investors considering CMPS, it's worth noting that InvestingPro offers 11 additional tips that could provide further insights into the company's prospects. These additional tips could be particularly valuable given the evolving situation at Compass Pathways and the revised outlook from analysts like H.C. Wainwright.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.